Bruce A. Cree MD
Neuroimmunology/Multiple Sclerosis
Associate Clinical Professor, Neurology, UCSF School of Medicine
Join to View Full Profile
1500 Owens St, Suite 320San Francisco, CA 94158
Phone+1 415-353-2069
Fax+1 415-353-2633
Dr. Cree is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Bruce Cree, MD, is a neurologist based in San Francisco, CA, specializing in neuroimmunology with a focus on multiple sclerosis. He completed his medical education (MD and Phd in Biochemistry) at the University of California San Francisco School of Medicine, an internship in internal medicine at California Pacific Medical Center, and a neurology residency at New York Presbyterian Hospital. Following residency he completed a fellowship in Neuroimmunology at the University of California San Francisco during which he earned a Masters in Advanced Studies in Clinical Research. He has contributed to over 300 peer-reviewed publications related to multiple sclerosis and other inflammatory diseases of the central nervous system such as neuromyelitis optica, optic neuritis and myelitis. He has engaged and led multiple clinical trials, serving as the principal investigator on studies involving treatments like ocrelizumab, inebilizumab, rituximab, ublituximab, fingolimod, ozanimod, siponimod, and tolebrutinib. Dr. Cree has been recognized as a Regional Top Doctor and achieved CMS Meaningful Use Stage 1 Certification. He currently serves as the Clinical Research Director in the Division of Neuroimmunology and Glial Biology in the Department of Neurology at the University of California San Francisco where he is a Professor of Clinical Neurology and is the George A. Zimmermann endowed Professor in Multiple Sclerosis.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1998 - 2001
Sutter Health/California Pacific Medical CenterInternship, Internal Medicine, 1997 - 1998
University of California San Francisco School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 2001 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Safety and Tolerability of Rituximab in Neuromyelitis Optica Start of enrollment: 2004 Jan 01
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.Bruce A C Cree, Joseph R Berger, Benjamin Greenberg
CNS Drugs. 2025-04-03 - Update on novel multiple sclerosis treatments: from dismal defeat to scintillating success.Bruce Cree, Hans-Peter Hartung
Current Opinion in Neurology. 2025-03-27 - No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies.Valerie J Block, Kyra Henderson, Shane Poole, Gabby B Joseph, Jeffrey M Gelfand
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 2025-03-25
Lectures
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Pittsburgh, Pennsylvania - 5/4/2013
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Cleveland, Ohio - 4/27/2013
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Denver, Colorado - 4/20/2013
- Join now to see all
Press Mentions
Can Central Vein Sign Distinguish Multiple Sclerosis from Its Most Common Mimic?March 20th, 2025- Smoldering MS May Warrant Unique Diagnosis, Treatment, and Research StrategiesNovember 7th, 2024
- How Progressive Multiple Sclerosis Differs from Relapsing-Remitting MSAugust 27th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
